Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, Piperno-Neumann S, Lantz O, Asselain B, Plancher C, Robert D, Péguillet I, Donnadieu MH, Dahmani A, Bessard MA, Gentien D, Reyes C, Saule S, Barillot E, Roman-Roman S, Decaudin D. Némati F, et al. Clin Cancer Res. 2010 Apr 15;16(8):2352-62. doi: 10.1158/1078-0432.CCR-09-3066. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371695
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients.
Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, Hupe P, Plancher C, Reyes C, Albaud B, Rapinat A, Gentien D, Couturier J, Sastre-Garau X, Desjardins L, Thiery JP, Roman-Roman S, Asselain B, Barillot E, Piperno-Neumann S, Saule S. Laurent C, et al. Cancer Res. 2011 Feb 1;71(3):666-74. doi: 10.1158/0008-5472.CAN-10-0605. Epub 2010 Dec 6. Cancer Res. 2011. PMID: 21135111
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C. Julien S, et al. Clin Cancer Res. 2012 Oct 1;18(19):5314-28. doi: 10.1158/1078-0432.CCR-12-0372. Epub 2012 Jul 23. Clin Cancer Res. 2012. PMID: 22825584
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T. Maire V, et al. Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9. Cancer Res. 2013. PMID: 23144294
Patient-derived xenografts recapitulate molecular features of human uveal melanomas.
Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat A, Sastre-Garau X, Couturier J, Hupé P, de Koning L, Dubois T, Roman-Roman S, Stern MH, Barillot E, Harbour JW, Saule S, Decaudin D. Laurent C, et al. Mol Oncol. 2013 Jun;7(3):625-36. doi: 10.1016/j.molonc.2013.02.004. Epub 2013 Feb 26. Mol Oncol. 2013. PMID: 23478236 Free PMC article.
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E. Cottu P, et al. Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947930
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, Camonis J, Desjardins L, Cassoux N, Piperno-Neumann S, Mariani P, Sastre X, Decaudin D, Roman-Roman S. Amirouchene-Angelozzi N, et al. Mol Oncol. 2014 Dec;8(8):1508-20. doi: 10.1016/j.molonc.2014.06.004. Epub 2014 Jun 13. Mol Oncol. 2014. PMID: 24994677 Free PMC article.
Upcoming translational challenges for uveal melanoma.
Amirouchene-Angelozzi N, Schoumacher M, Stern MH, Cassoux N, Desjardins L, Piperno-Neumann S, Lantz O, Roman-Roman S. Amirouchene-Angelozzi N, et al. Br J Cancer. 2015 Nov 3;113(9):1249-53. doi: 10.1038/bjc.2015.269. Epub 2015 Oct 27. Br J Cancer. 2015. PMID: 26505679 Free PMC article. Review.
Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.
Crépin R, Gentien D, Duché A, Rapinat A, Reyes C, Némati F, Massonnet G, Decaudin D, Djender S, Moutel S, Desrumeaux K, Cassoux N, Piperno-Neumann S, Amigorena S, Perez F, Roman-Roman S, de Marco A. Crépin R, et al. Pigment Cell Melanoma Res. 2017 May;30(3):317-327. doi: 10.1111/pcmr.12577. Epub 2017 Apr 19. Pigment Cell Melanoma Res. 2017. PMID: 28140525
168 results